Global Artificial Hearts and Circulatory Assist Market Size By Type (Ventricular Assist Devices, Artificial Heart), By Application (Coronary Heart Disease, Cerebrovascular Disease), By Region, And Seg...

The Global Artificial Hearts and Circulatory Assist Market was valued at USD 4.7 billion in 2023 and is projected to surpass USD 10.9 billion by 2031, expanding at a CAGR of 11.2% from 2023 to 2031. The surge in demand for mechanical circulatory support (MCS) devices is primarily driven by the rising prevalence of cardiovascular diseases (CVDs), increasing geriatric population, and advancements in biomedical engineering. Artificial hearts and circulatory assist devices such as ventricular assist devices (VADs) and total artificial hearts (TAHs) are critical life-saving technologies for patients with end-stage heart failure or awaiting heart transplants.

Drivers:

Rising Prevalence of Cardiovascular Diseases:

Globally, cardiovascular conditions remain the leading cause of mortality. With an increase in lifestyle-related factors such as obesity, hypertension, and diabetes, the demand for advanced cardiac support systems is growing steadily.

Technological Innovations in Circulatory Assist Devices:

Continual R&D efforts have led to the development of next-generation VADs and TAHs with improved biocompatibility, miniaturized design, longer durability, and reduced infection risk—enhancing patient outcomes and device longevity.

Growing Aging Population:

The expanding geriatric demographic is more susceptible to heart failure and other cardiac ailments, thus increasing the demand for artificial circulatory support systems as a bridge-to-transplant or destination therapy.

Restraints:

High Costs and Limited Accessibility:

The considerable costs associated with device procurement, surgical implantation, and post-operative care pose a significant barrier, particularly in low- and middle-income countries.

Complex Surgical Procedures and Risk Factors:

Implantation of circulatory assist devices requires complex procedures often accompanied by risks such as bleeding, infection, and thrombosis, limiting their widespread use.

Opportunity:

Expansion in Emerging Markets:

Countries in Asia-Pacific and Latin America are witnessing growth in healthcare investments and cardiac care infrastructure, offering untapped potential for device manufacturers.

Integration with Telemonitoring and AI-Based Diagnostics:

The convergence of circulatory assist technologies with remote monitoring and artificial intelligence can enhance real-time device performance tracking and patient care, opening new frontiers in personalized treatment.

Market by System Type Insights:

The Ventricular Assist Devices (VADs) segment dominated the market in 2023, accounting for the largest revenue share. VADs are extensively used for patients with severe heart failure as a bridge-to-transplant or as destination therapy. Continuous-flow VADs, in particular, are witnessing increased adoption due to their enhanced durability and compact size.

Meanwhile, Total Artificial Hearts (TAHs) are gaining traction in specific high-risk cases where both ventricles are non-functional. Although still in the early stages of adoption, their potential as a long-term solution is growing with product approvals and clinical trials.

Market by End-Use Insights:

In 2023, Hospitals emerged as the leading end-use segment due to their capabilities in conducting complex surgical procedures and post-operative care. The segment benefits from the increasing number of heart failure hospitalizations and the availability of specialized cardiac care units.

Ambulatory Surgical Centers (ASCs) are projected to exhibit the highest growth rate due to the push towards outpatient cardiac interventions, cost-effectiveness, and improvements in minimally invasive surgical techniques.

Market by Regional Insights:

North America held the largest share of the global market in 2023, supported by a robust healthcare system, significant reimbursement policies, and early adoption of advanced technologies. The U.S., in particular, is a leader in heart transplant programs and MCS device usage.

Asia-Pacific is expected to be the fastest-growing region during the forecast period. Rapidly improving healthcare infrastructure, increasing awareness, and supportive government initiatives in countries like China and India are driving growth in the region.

Competitive Scenario:

Prominent players in the global artificial hearts and circulatory assist market include Abbott Laboratories, Medtronic plc, SynCardia Systems LLC, Abiomed Inc., Jarvik Heart Inc., Berlin Heart GmbH, Calon Cardio, CARMAT SA, CorWave, and FineHeart. These companies are focused on:

FDA and CE mark approvals for new-generation devices

Strategic mergers and acquisitions to expand geographic footprint

Collaborations with research institutions for clinical trial advancements

Key Market Developments:

2023: SynCardia Systems LLC initiated a Phase II clinical trial for its next-gen total artificial heart.

2024: Abbott Laboratories received FDA approval for its updated HeartMate 3 LVAD with enhanced software.

2025: Medtronic launched a compact, wireless VAD platform for pediatric applications across select markets in Europe.

Scope of Work – Global Artificial Hearts and Circulatory Assist Market

Report Metric Details

Market Size (2023) USD 4.7 billion

Projected Market Size (2031) USD 10.9 billion

CAGR (2023–2031) 11.2%

Market Segments By System Type (VADs, TAHs), By End-Use, Region

Growth Drivers Rising cardiovascular disease burden, aging population, and technological innovation

Opportunities Emerging markets and integration with digital monitoring technologies

FAQs:

What is the current market size of the Global Artificial Hearts and Circulatory Assist Market?

The market was valued at USD 4.7 billion in 2023.

What is the major growth driver of the Global Artificial Hearts and Circulatory Assist Market?

The primary growth driver is the rising prevalence of cardiovascular diseases and technological advancements in circulatory support systems.

Which is the largest region during the forecast period in the Global Artificial Hearts and Circulatory Assist Market?

North America is projected to remain the dominant region due to early technology adoption and strong healthcare infrastructure.

Which segment accounted for the largest market share in the Global Artificial Hearts and Circulatory Assist Market?

The Ventricular Assist Devices (VADs) segment held the largest share in 2023.

Who are the key market players in the Global Artificial Hearts and Circulatory Assist Market?

Key players include Abbott Laboratories, Medtronic plc, SynCardia Systems LLC, Abiomed Inc., Berlin Heart GmbH, and CARMAT SA.